Semaglutide

Semaglutide (a human glucagon-like peptide-1 (GLP-1) analog produced by genetic recombination technology using Saccharomyces cerevisiae cells). 1 ml of injection solution contains 1.34 mg of semaglutide. Each prefilled injection pen contains 2 mg of semaglutide in 1.5 ml of solution.

Semaglutide can delay gastric emptying and may affect the absorption rate of oral medications taken at the same time. Patients taking oral medications that require rapid gastrointestinal absorption should use this product with caution. Paracetamol The pharmacokinetics of paracetamol during a standard meal test showed that semaglutide can delay the rate of gastric emptying. When co-administered with 1 mg of this product, the area under the 0-60 minute concentration curve (AUCo.60min) and peak concentration (Cmx) of paracetamol decreased by 27% and 23%, respectively. The total exposure of paracetamol (AUCo.sh) was not affected. No dose adjustment of paracetamol is required for co-administration with this product. Oral contraceptives Semaglutide is not expected to reduce the efficacy of oral contraceptives, because the effect of semaglutide on the total exposure of ethinyl estradiol and levonorgestrel when the oral contraceptive combination (0.03 mg ethinyl estradiol/0.15 mg levonorgestrel) is not clinically significant. The exposure of ethinyl estradiol was not affected; the exposure of levonorgestrel increased by 20% at steady state. The peak concentration (Cmax) of each component of the combination was not affected. Atorvastatin semaglutide did not change the total exposure of atorvastatin after a single dose (40 mg). The peak concentration (Cmax) of atorvastatin decreased by 38%. The change was assessed to be clinically insignificant. Digoxin semaglutide did not change the total exposure and peak concentration (Cmax) of digoxin after a single dose (0.5 mg). Metformin semaglutide did not change the total exposure and peak concentration (Cmax) of metformin after 500 mg twice daily for 3.5 days. Warfarin semaglutide does not change the total exposure or peak concentration (Cmax) of R- and S-warfarin after a single dose of warfarin (25 mg). The international normalized ratio (INR) test found that semaglutide had no clinically significant effect on the pharmacodynamics of warfarin. However, when patients taking warfarin and/or other coumarin derivatives start treatment with this product, frequent monitoring of INR is still recommended. Incompatibility This product must not be mixed with other drugs without conducting a compatibility study.

Semaglutide (a human glucagon-like peptide-1 (GLP-1) analog produced by genetic recombination technology using Saccharomyces cerevisiae cells). 1 ml of injection solution contains 1.34 mg of semaglutide. Each prefilled injection pen contains 2 mg of semaglutide in 1.5 ml of solution.

Semaglutide can delay gastric emptying and may affect the absorption rate of oral medications taken at the same time. Patients taking oral medications that require rapid gastrointestinal absorption should use this product with caution. Paracetamol The pharmacokinetics of paracetamol during a standard meal test showed that semaglutide can delay the rate of gastric emptying. When co-administered with 1 mg of this product, the area under the 0-60 minute concentration curve (AUCo.60min) and peak concentration (Cmx) of paracetamol decreased by 27% and 23%, respectively. The total exposure of paracetamol (AUCo.sh) was not affected. No dose adjustment of paracetamol is required for co-administration with this product. Oral contraceptives Semaglutide is not expected to reduce the efficacy of oral contraceptives, because the effect of semaglutide on the total exposure of ethinyl estradiol and levonorgestrel when the oral contraceptive combination (0.03 mg ethinyl estradiol/0.15 mg levonorgestrel) is not clinically significant. The exposure of ethinyl estradiol was not affected; the exposure of levonorgestrel increased by 20% at steady state. The peak concentration (Cmax) of each component of the combination was not affected. Atorvastatin semaglutide did not change the total exposure of atorvastatin after a single dose (40 mg). The peak concentration (Cmax) of atorvastatin decreased by 38%. The change was assessed to be clinically insignificant. Digoxin semaglutide did not change the total exposure and peak concentration (Cmax) of digoxin after a single dose (0.5 mg). Metformin semaglutide did not change the total exposure and peak concentration (Cmax) of metformin after 500 mg twice daily for 3.5 days. Warfarin semaglutide does not change the total exposure or peak concentration (Cmax) of R- and S-warfarin after a single dose of warfarin (25 mg). The international normalized ratio (INR) test found that semaglutide had no clinically significant effect on the pharmacodynamics of warfarin. However, when patients taking warfarin and/or other coumarin derivatives start treatment with this product, frequent monitoring of INR is still recommended. Incompatibility This product must not be mixed with other drugs without conducting a compatibility study.